The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Pathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Abstract
Castleman's disease is a syndrome consisting of giant lymph node hyperplasia with plasma cell infiltration, fever, anemia, hypergammaglobulinemia, and an increase in the plasma level of acute phase proteins. It has been reported that clinical abnormalities disappear after the resection of the affected lymph nodes, suggesting that products of lymph nodes may cause such clinical abnormalities. Interleukin-6 (IL-6) is a cytokine inducing B-cell differentiation to immunoglobulin-producing cells and regulating biosynthesis of acute phase proteins. This report demonstrates that the germinal centers of hyperplastic lymph nodes of patients with Castleman's disease produce large quantities of IL-6 without any significant production of other cytokines. In a patient with a solitary hyperplastic lymph node, clinical improvement and decrease in serum IL-6 were observed following surgical removal of the involved lymph node. There was a correlation between serum IL-6 level, lymph node hyperplasia, hypergammaglobulinemia, increased level of acute phase proteins, and clinical abnormalities. The findings in this report indicate that the generation of IL-6 by B cells in germinal centers of hyperplastic lymph nodes of Castleman's disease may be the key element responsible for the variety of clinical symptoms in this disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies in the 1980s also showed that IL-6 is produced by cardiac myxoma cells (42) and Castleman’s germinal center cells (43)”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [43]
In the citing paper
“Generally, surgical removal of hyperplastic lymph nodes results in symptomatic improvement and reduced serum IL-6 concentrations (Yoshizaki et al., 1989”
From Targeting Interleukin-6 Signaling in Clinic (2019) · cites this paper as Yoshizaki et al., 1989
Citations
Cites
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Self-citationHirano, T., Taga, T., Yasukawa, K., Nakajima, K., Nakano, N., Takatsuki, F., Shimizu, M., Murashima, A., Tsunasawa, S., & Sakiyama, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.228 · Cited by 351
Cited by
Sorted by citations
Items 101–200 of 489
Kawabata, H., Tomosugi, N., Kanda, J., Tanaka, Y., Yoshizaki, K., & Uchiyama, T. (2007) · Haematologica · doi:10.3324/haematol.10794 · Cited by 87
Self-citationShacter, E., Arzadon, G., & Williams, J. A. (1992) · Blood · doi:10.1182/blood.v80.1.194.bloodjournal801194 · Cited by 86
Kawabata, H., Kadowaki, N., Nishikori, M., Kitawaki, T., Kondo, T., Ishikawa, T., Yoshifuji, H., Yamakawa, N., Imura, Y., Mimori, T., et al. (2013) · Journal of Clinical and Experimental Hematopathology · doi:10.3960/jslrt.53.69 · Cited by 85
Urken, M. L., Milas, M., Randolph, G. W., Tufano, R. P., Bergman, D. A., Bernet, V. J., Brett, E. M., Brierley, J. D., Cobin, R. H., Doherty, G. M., et al. (2014) · Head & Neck · doi:10.1002/hed.23615 · Cited by 88
Screpanti, I., Musiani, P., Bellavia, D., Cappelletti, M., Aiello, F. B., Maroder, M., Frati, L., Modesti, A., Gulino, A., & Poli, V. (1996) · Journal of Experimental Medicine · doi:10.1084/jem.184.4.1561 · Cited by 83
“The germinal centers from affected lymph nodes produce considerable amounts of this cytokine, whose circulating levels directly correlate with clinical manifestations (2).”
BackgroundCastleman disease and associated autoimmune disease
Muskardin, T. W., Peterson, B. A., & Molitor, J. A. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834db525 · Cited by 80
“[35] reported the elaboration of IL-6 from germinal centers of lymph nodes in patients with plasma cell-variant unicentric Castleman disease and multicentric Castleman disease.”
BackgroundInoue, M., Ankou, M., Jiang, H., Iwaki, Y., Hagihara, M., & Ota, Y. (2013) · Journal of Clinical and Experimental Hematopathology · doi:10.3960/jslrt.53.95 · Cited by 79
Ruco, L., Gearing, A., Pigott, R., Pomponi, D., Burgio, V. L., Cafolla, A., Baiocchini, A., & Baroni, C. (1991) · Histopathology · doi:10.1111/j.1365-2559.1991.tb01500.x · Cited by 76
Cytokines Involved in B-Cell Differentiation and Their Sites of Action
Takatsu, K. (1997) · Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine · doi:10.3181/00379727-215-44119 · Cited by 76
Essential Role of IL-6 Signaling Pathway in Keloid Pathogenesis
Ghazizadeh, M. (2007) · Journal of Nippon Medical School · doi:10.1272/jnms.74.11 · Cited by 73
Kawabata, H., Kotani, S., Matsumura, Y., Kondo, T., Katsurada, T., Haga, H., Kadowaki, N., & Takaori-Kondo, A. (2013) · Internal medicine · doi:10.2169/internalmedicine.52.9482 · Cited by 71
“Interleukin-6 (IL6) is thought to play a central role in the clinical manifestations of MCD (3).”
BackgroundDanon, A., Krishnan, J., & Frizzera, G. (2005) · Virchows Archiv · doi:10.1007/bf01607150 · Cited by 71
“~989; Isaacson 1989) and that the stimulus to their proliferation and differentiation to PCs could come from excessive interleukin-6 (IL-6) production by the hyperplastic GCs (Yoshizaki et al. 1989; Leger-Ravet et al. 1991).”
BackgroundZhang, X., Rao, H., Xu, X., Li, Z., Liao, B., Wu, H., Li, M., Tong, X., Li, J., & Cai, Q. (2017) · Cancer Science · doi:10.1111/cas.13439 · Cited by 69
Intracellular Signaling Mechanisms and Activities of Human Herpesvirus 8 Interleukin-6
Chen, D., Sandford, G., & Nicholas, J. (2008) · Journal of Virology · doi:10.1128/jvi.01517-08 · Cited by 70
“The cancers with which human herpesvirus 8 (HHV-8) is associated, Kaposi’s sarcoma (KS), multicentric Castleman’s disease, and primary effusion lymphoma (PEL), are all diseases in which interleukin-6 (IL-6) signaling is believed to play an important role, either as a driver of cell growth and survival or as an inducer…”
BackgroundAlleviation of systemic manifestations of multicentric Castleman's disease by thalidomide
Lee, F., & Merchant, S. H. (2003) · American journal of hematology/oncology · doi:10.1002/ajh.10310 · Cited by 68
“A high level of IL-6 has been reported in patients with MCD and has been implicated in the pathogenesis of the disease [33].”
BackgroundElevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome
Iwaki, N., Gion, Y., Kondo, E., Kawano, M., Masunari, T., Moro, H., Nikkuni, K., Takai, K., Hagihara, M., Hashimoto, Y., et al. (2017) · Scientific Reports · doi:10.1038/srep42316 · Cited by 67
Straatsburg, I. H., Boermeester, M. A., Houdijk, A. P. J., Frederiks, W. M., Wesdorp, R. I. C., van Leeuwen, P. A. M., & Noorden, C. J. F. V. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199605)179:1 · Cited by 12
Bruno, E., Cooper, R. J., Briddell, R., & Hoffman, R. (1991) · Blood · doi:10.1182/blood.v77.11.2339.bloodjournal77112339 · Cited by 67
Iwaki, N., Sato, Y., Takata, K., Kondo, E., Ohno, K., Takeuchi, M., Orita, Y., Nakao, S., & Yoshino, T. (2013) · Journal of Clinical and Experimental Hematopathology · doi:10.3960/jslrt.53.87 · Cited by 66
Kaposi Sarcoma Pathogenesis: A Triad of Viral Infection, Oncogenesis and Chronic Inflammation
Douglas, J. L., Gustin, J. K., Moses, A., Dezube, B., & Pantanowitz, L. (2010) · Translational Biomedicine · doi:10.3823/409 · Cited by 65
Review: Human Gammaherpesvirus Cytokines and Chemokine Receptors
Nicholas, J. (2005) · Journal of Interferon and Cytokine Research · doi:10.1089/jir.2005.25.373 · Cited by 64
“22) vIL-6 shares mitogenic and other properties of its cellular counterpart and, in addition, can signal more promiscuously as it is not dependent on the gp80/IL-6R (cid:2) -subunit of the IL-6R complex for signaling.”
Castleman's disease—a two compartment model of HHV8 infection
Schulte, K., & Talat, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.103 · Cited by 63
Goya, S., Matsuoka, H., Mori, M., Morishita, H., Kida, H., Kobashi, Y., Kato, T., Taguchi, Y., Osaki, T., Tachibana, I., et al. (2003) · Journal of Pathology · doi:10.1002/path.1321 · Cited by 62
“In the development of some lymphoproliferative diseases, namely those involving the lung parenchyma, interleukin (IL)-6 is known to play an important role [1,2].”
BackgroundSelf-citationTabata, C., Kubo, H., Tabata, R., Wada, M., Sakuma, K., Ichikawa, M., Fujita, S., Mio, T., & Mishima, M. (2005) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00282.2005 · Cited by 54
“disorders, such as Castleman’s disease (48), collagen-induced”
Significance of interleukin-6 in patients with inflammatory bowel disease
Mitsuyama, K., Sata, M., & Tanikawa, K. (1991) · Gastroenterologia Japonica · doi:10.1007/bf02779504 · Cited by 60
Aryl hydrocarbon receptor and experimental autoimmune arthritis
Nguyen, N. T., Nakahama, T., & Kishimoto, T. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-013-0392-6 · Cited by 66
Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease
Montani, D., Achouh, L., Marcelin, A., Viard, J., Hermine, O., Canioni, D., Sitbon, O., Simonneau, G., & Humbert, M. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00133904 · Cited by 58
Hirano, T., & Kishimoto, T. (1990) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-49295-2_14 · Cited by 57
Treatment of Kaposi sarcoma herpesvirus-associated multicentric Castleman disease
Lurain, K., Yarchoan, R., & Uldrick, T. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2017.09.007 · Cited by 54
Ogata, A., & Tanaka, T. (2012) · International Journal of Rheumatology · doi:10.1155/2012/946048 · Cited by 54
“Subsequent studies have shown that dysregulation of IL-6 production is implicated in the pathogenesis of Castleman’s disease [11], rheumatoid arthritis (RA) [12], and various other autoimmune, inflammatory, and malignant diseases [2–4].”
BackgroundHuman herpesvirus 8-encoded proteins with potential roles in virus-associated neoplasia.
Nicholas, J. (2007) · Frontiers in Bioscience · doi:10.2741/2063 · Cited by 54
“268 disease severity (20, 21) and can support the clonal growth of PEL cells (22).”
BackgroundNaqash, A., Yang, L. V., Sanderlin, E., Atwell, D. C., & Walker, P. (2017) · Acta oncologica · doi:10.1080/0284186x.2017.1406668 · Cited by 53
Toma, M., & Tawa, K. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b06917 · Cited by 63
Amin, H., Medeiros, L., Manning, J. T., & Jones, D. M. (2003) · American Journal of Surgical Pathology · doi:10.1097/00000478-200301000-00010 · Cited by 53
“Castleman’s disease associated with plasmacytosis show increased levels of interleukin (IL)-6.(8,50) This cytokine is”
BackgroundMorra, D. E., Pierson, S., Shilling, D. J., Nemat, S., Appiani, C., Guilfoyle, M., Tendler, C., van Rhee, F., & Fajgenbaum, D. (2018) · British Journal of Haematology · doi:10.1111/bjh.15588 · Cited by 52
IL-1RA Agonist (Anakinra) in the Treatment of Multifocal Castleman Disease: Case Report
Galeotti, C., Tran, T., Franchi-Abella, S., Fabre, M., Pariente, D., & Koné-Paut, I. (2008) · Journal of pediatric hematology/oncology · doi:10.1097/mph.0b013e31818ab31f · Cited by 52
Current status and prospects of IL-6–targeting therapy
Narazaki, M., & Kishimoto, T. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2097905 · Cited by 55
Fujimoto, S., Koga, T., Kawakami, A., Kawabata, H., Okamoto, S., Mizuki, M., Yano, S., Ide, M., Uno, K., Yagi, K., et al. (2018) · Modern Rheumatology · doi:10.1080/14397595.2017.1366093 · Cited by 50
“increased level of IL-6 in the serum [8,28].”
BackgroundSelf-citationCastleman's disease in childhood: report of three cases and review of the literature
Farruggia, P., Trizzino, A., Scibetta, N., Cecchetto, G., Guerrieri, P., d'Amore, E., & D'Angelo, P. (2011) · Italian Journal of Pediatrics · doi:10.1186/1824-7288-37-50 · Cited by 50
“It is postulated that the disease represents a reaction to chronic viral antigenic stimulation with the bulk of evidence pointing toward an interleukin-6 role, above all in the form of the disease associated with systemic manifestations [15-17].”
BackgroundInterleukin-6 signal transduction and its role in hepatic lipid metabolic disorders
Hassan, W., Ding, L., Gao, R.-Y., Liu, J., & Shang, J. (2014) · Cytokine · doi:10.1016/j.cyto.2013.12.017 · Cited by 51
“Evidence supporting the involvement of IL-6 in modulating lipid metabolism is that patients with Castleman’s disease have shown abnormal secretion of IL-6 in their B-cells in the germinal centers of hyperplastic lymph nodes [15] and this is coincided with the state of hypolipidaemia [116].”
BackgroundAoyama, A., Endo‐Umeda, K., Kishida, K., Ohgane, K., Noguchi‐Yachide, T., Aoyama, H., Ishikawa, M., Miyachi, H., Makishima, M., & Hashimoto, Y. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3002394 · Cited by 60
Menke, D. M., Chadburn, A., Cesarman, E., Green, E., Berenson, J. R., SAID, J. W., Tiemann, M., Parwaresch, R. M., & Thomé, S. D. (2002) · American Journal of Clinical Pathology · doi:10.1309/7243-av50-kj28-v6j9 · Cited by 44
Ishiyama, T., Nakamura, S., Akimoto, Y., Koike, M., Tomoyasu, S., Tsuruoka, N., Murata, Y., Sato, T., Wakabayashi, Y., & Chiba, S. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04777.x · Cited by 48
Yamamoto, M., Takahashi, H., Hasebe, K., Suzuki, C., Naishiro, Y., Hayashi, T., Yamamoto, H., Ishida, T., & Shinomura, Y. (2009) · Rheumatology · doi:10.1093/rheumatology/kep098 · Cited by 47
Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukemia.
Inoue, K., Sugiyama, H., Ogawa, H., Yamagami, T., Azuma, T., Oka, Y., Miwa, H., Kita, K., Hiraoka, A., & Masaoka, T. (1994) · Blood · doi:10.1182/blood.v84.8.2672.bloodjournal8482672 · Cited by 47
Interleukin-6 in clinical medicine
Bauer, J., & Herrmann, F. (1991) · Annals of Hematology · doi:10.1007/bf01729833 · Cited by 128
Iron-deficiency anemia in Castleman disease: implication of the interleukin 6/hepcidin pathway
Arlet, J.-B., Hermine, O., Darnige, L., Ostland, V., Westerman, M., Badoual, C., Pouchot, J., & Capron, L. (2010) · PEDIATRICS · doi:10.1542/peds.2010-1123 · Cited by 46
Review of siltuximab in the treatment of multicentric Castleman’s disease
Sarosiek, S., Shah, R., & Munshi, N. (2016) · Therapeutic Advances in Hematology · doi:10.1177/2040620716653745 · Cited by 46
“IL-6 levels typically correlate with the clinical course and therefore are thought to be the etiology of constitutional symptoms [Yoshizaki et al. 1989].”
BackgroundResultFujiwara, S., Mochinaga, H., Nakata, H., Ohshima, K., Matsumoto, M., Uchiba, M., Mikami, Y., Hata, H., Okuno, Y., Mitsuya, H., et al. (2016) · International journal of hematology · doi:10.1007/s12185-016-1978-2 · Cited by 46
“were the first to report IL-6 production in lymph nodes of patients with CD [18].”
BackgroundWang, R., Li, J., Wang, M.-Y., Hao, H., Chen, X.-X., Li, R., & Zhu, X. (2015) · British Journal of Dermatology · doi:10.1111/bjd.13525 · Cited by 46
Multicentric Castleman's disease in HIV infection
Collins, L., Fowler, A., Tong, C., & de Ruiter, A. (2006) · International Journal of STD and AIDS · doi:10.1258/095646206775220496 · Cited by 46
Pierson, S. K., Shenoy, S. A., Oromendia, A. B., Gorzewski, A. M., Pai, R.-A. L., Nabel, C. S., Ruth, J. R., Parente, S. A. T., Arenas, D. J., Guilfoyle, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004016 · Cited by 50
“Although etiology is unknown, interleukin-6 (IL-6) has been identified as a disease driver in a portion of patients.(6,7) IL-6 is a pleiotropic cytokine that leads to activation of signaling pathways associated with survival and proliferation, most notably the Janus kinase/signal transducer and activator of transcript…”
BackgroundÉmilie, D., Ftor, R., Llorente, L., Marfaing‐Koka, A., Peuchmaur, M. M., Devergne, O., Jarrousse, B., Wijdenes, J., Boue, F., & Galanaud, P. (1994) · Immunological Reviews · doi:10.1111/j.1600-065x.1994.tb00863.x · Cited by 40
Mei, Y., Ren, K.-H., Liu, Y.-J., Ma, A., Xia, Z., Han, X., Li, E., Tariq, H., Bao, H., Xie, X., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci152673 · Cited by 44
“While the pathophysiology of IL-6 signaling in several lymphoid neoplasms has been well studied (46–49), the roles of IL-6 in MDS remain observational.”
Soluble cytokine receptors in biological therapy
Fernandez-Botrán, R., Sun, X., & Crespo, F. A. (2002) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2.6.585 · Cited by 39
Otani, K., Inoue, D., Fujikura, K., Komori, T., Abe-Suzuki, S., Tajiri, T., Itoh, T., & Zen, Y. (2015) · OncoTarget · doi:10.18632/oncotarget.24068 · Cited by 43
Self-citationClinical spectrum of Castleman disease–associated neuropathy
Naddaf, E., Dispenzieri, A., Mandrekar, J., & Mauermann, M. L. (2016) · Neurology · doi:10.1212/wnl.0000000000003405 · Cited by 41
Fajgenbaum, D., Ruth, J., Kelleher, D., & Rubenstein, A. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)00007-7 · Cited by 41
Arita, Y., Sakata, Y., Sudo, T., Maeda, T., Matsuoka, K., Tamai, K., Higuchi, K., Shioyama, W., Nakaoka, Y., Kanakura, Y., et al. (2010) · Heart and Vessels · doi:10.1007/s00380-009-1215-5 · Cited by 41
Perfetti, V., Bellotti, V., Maggi, A., Arbustini, E., de Benedetti, F., Paulli, M., Marinone, M., & Merlini, G. (1994) · American journal of hematology/oncology · doi:10.1002/ajh.2830460306 · Cited by 41
Interleukin‐6 secreting phaeochromocytoma associated with clinical markers of inflammation
Takagi, M., Egawa, T., Motomura, T., Sakuma-Mochizuki, J., Nishimoto, N., Kasayama, S., Hayashi, S., Koga, M., Yoshizaki, K., Yoshioka, T., et al. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.1160931.x · Cited by 40
“Immunohistochemical study by the avidin-biotin peroxidase technique, using mouse anti-human IL-6 monoclonal antibody (Yoshizaki et al., 1989), revealed that the tumour cells were positively stained for IL-6 (Fig.”
MethodSelf-citationTanner, J., & Menézes, J. (1994) · Blood · doi:10.1182/blood.v84.11.3956.bloodjournal84113956 · Cited by 39
Interleukin‐6 production and secretion by human parathyroids
Safley, S., Villinger, F., Jackson, E., Tucker-Burden, C., Cohen, C., & Weber, C. (2004) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2004.02419.x · Cited by 38
Hess, G., Wagner, V., Kreft, A., Heussel, C., & Huber, C. (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06212.x · Cited by 37
“This is supported by the observed normalisation of IL-6 levels, paraproteinemia and clinical symptoms after surgical resection of unilocular disease (Yoshizaki et al, 1989).”
BackgroundCastleman’s Disease and Mesangial Proliferative Glomerulonephritis: The Role of Interleukin-6
Lui, S., Chan, K. W., Li, F.-K., Cheng, I. K., & Chan, T. (1998) · Nephron · doi:10.1159/000044943 · Cited by 37
Human Herpesvirus 8 and Lymphoproliferative Disorders
Calabrò, M., & Sarid, R. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.061 · Cited by 36
The role of tocilizumab in the management of rheumatoid arthritis
Ash, Z. R., & Emery, P. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707178 · Cited by 30
Cytokine Homologs of Human Gammaherpesviruses
Sin, S.-H., & Dittmer, D. (2012) · Journal of Interferon and Cytokine Research · doi:10.1089/jir.2011.0083 · Cited by 36
Preston, G., Barrett, C. V., Alcorta, D., Hogan, S., Dinwiddie, L., Jennette, J., & Falk, R. (2002) · Nephron · doi:10.1159/000065464 · Cited by 36
Cousins, E., & Nicholas, J. (2013) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-38965-8_13 · Cited by 47
“In MCD patients, levels of IL-6 are substantially higher in affected lymph nodes when compared to unaffected nodes of the same patient (Yoshizaki et al. 1989).”
BackgroundKozina, E. A., Byrne, M. D., & Smeyne, R. J. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00289-9 · Cited by 39
Established and Emerging Concepts to Treat Imbalances of Iron Homeostasis in Inflammatory Diseases
Petzer, V., Theurl, I., & Weiß, G. (2018) · Pharmaceuticals · doi:10.3390/ph11040135 · Cited by 41
“Accordingly, targeted therapy using an anti-IL6 receptor antibody (Tocilizumab) improved anemia in patients suffering from multicentric Castleman’s disease (MCD), a lymphoproliferative disorder where IL6 was found to be the main cytokine contributing to its pathogenesis [101,102].”
BackgroundSong, J., Ohkura, T., Sugimoto, M., Mori, Y., Inagi, R., Yamanishi, K., Yoshizaki, K., & Nishimoto, N. (2002) · Journal of Medical Virology · doi:10.1002/jmv.10218 · Cited by 34
Self-citationNakazawa, K., Itoh, N., Shigematsu, H., & Koh, C. (1992) · Acta Pathologica Japonica · doi:10.1111/j.1440-1827.1992.tb03046.x · Cited by 28
Sustained remission of Multicentric Castleman Disease in children treated with tocilizumab
Galeotti, C., Boucheron, A., Guillaume, S., & Koné-Paut, I. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0972 · Cited by 32
“MCD is linked to excessive production of IL-6 in the germinal centers (1).”
BackgroundDavies, K., Cope, A., Schofield, J., Chu, C.-Q., Mason, J., Krausz, T., Smith, P., Denman, A., & Walport, M. (1995) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1995.tb03481.x · Cited by 32
Yuan, Z.-G., Dun, X.-Y., Li, Y.-H., & Hou, J. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-19 · Cited by 31
“In recent 10 years, IL-6 has been implicated in the pathophysiology of MCD[5].”
BackgroundKojima, M., Miyawaki, S., Takada, S., Kashiwabara, K., Igarashi, T., & Nakamura, S. (2008) · International Journal of Surgical Pathology · doi:10.1177/1066896907306969 · Cited by 31
Tokunaga, O., Watanabe, T., Shimamoto, Y., & Tokudome, S. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3 · Cited by 36
Transcriptome and unique cytokine microenvironment of Castleman disease
Wing, A., Xu, J. Z., Meng, W., Rosenfeld, A. M., Li, E. Y., Wertheim, G. B. W., Paessler, M. E., Bagg, A., Frank, D. M., Tan, K., et al. (2021) · Modern Pathology · doi:10.1038/s41379-021-00950-3 · Cited by 35
Elevated serum interleukin-6 levels in patients with acute hepatitis
Sun, Y., Tokushige, K., Isono, E., Yamauchi, K., & Obata, H. (1992) · Journal of Clinical Immunology · doi:10.1007/bf00918089 · Cited by 45
“In this regard, recent reports of abnormal behavior of these cytokines in certain human diseases are thought to be important for understanding in detail the mechanism of these diseases (12-15).”
Nishikori, A., Nishimura, M. F., Fajgenbaum, D. C., Nishimura, Y., Maehama, K., Haratake, T., Tabata, T., Kawano, M., Nakamura, N., Momose, S., et al. (2024) · Journal of Clinical Pathology · doi:10.1136/jcp-2023-209280 · Cited by 27
CXCL13 is a predictive biomarker in idiopathic multicentric Castleman disease
Pierson, S., Katz, L., Williams, R., Mumau, M. D., Gonzalez, M. V., Guzman, S., Rubenstein, A., Oromendia, A., Beineke, P., Fosså, A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34873-7 · Cited by 29
ADA2 Deficiency Mimicking Idiopathic Multicentric Castleman Disease
Nieuwenhove, E. V., Humblet-Baron, S., Eyck, L. V., Somer, L. D., Dooley, J., Tousseyn, T., Hershfield, M., Liston, A., & Wouters, C. (2018) · Pediatrics · doi:10.1542/peds.2017-2266 · Cited by 29
Wang, H., Wieczorek, R., Zenilman, M., Desoto-Lapaix, F., Ghosh, B., & Bowne, W. (2007) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-5-133 · Cited by 29
“Interestingly, lymph nodes from various animal models and patients with CD implicate IL-6 as a causative agent for the commonly observed systemic manifestations [20,26-29].”
BackgroundCastleman Disease Presenting with Jaundice: A Case with the Multicentric Hyaline Vascular Variant
Park, J. B., Hwang, J.-H., Kim, H., Choe, H., Kim, Y. K., Kim, H. B., & Bang, S. (2007) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2007.22.2.113 · Cited by 29
Abe, Y., Matsubara, D., Gatanaga, H., Oka, S., Kimura, S., Sasao, Y., Saitoh, K., Fujii, T., Sato, Y., Sata, T., et al. (2006) · Pathology international (Print) · doi:10.1111/j.1440-1827.2006.02017.x · Cited by 29
Burger, R., Wendler, J., Antoni, K., Helm, G., Kalden, J. R., & Gramatzki, M. (1994) · Annals of Hematology · doi:10.1007/bf01757344 · Cited by 45
Candidate biomarkers for idiopathic multicentric Castleman disease
Sumiyoshi, R., Koga, T., & Kawakami, A. (2022) · Journal of Clinical and Experimental Hematopathology · doi:10.3960/jslrt.22010 · Cited by 28
HMGB1-Mediated Early Loss of Transplanted Islets Is Prevented by Anti–IL-6R Antibody in Mice
Itoh, T., Nitta, T., Nishinakamura, H., Kojima, D., Mera, T., Ono, J., Kodama, S., & Yasunami, Y. (2015) · Pancreas · doi:10.1097/mpa.0000000000000188 · Cited by 28
Hayashi, M., Rho, M., Fukami, A., Enomoto, A., Nonaka, S., Sekiguchi, Y., Yanagisawa, T., Yamashita, A., Nogawa, T., Kamano, Y., et al. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.036137 · Cited by 28
“, 1992), Castleman’s disease (Yoshizaki et al., 1989), rheumatoid arthritis (Takagi et al.”
BackgroundHashizume, M., & Mihara, M. (2011) · Inflammation and Regeneration · doi:10.2492/inflammregen.31.325 · Cited by 28
Idiopathic multicentric Castleman disease: An update in diagnosis and treatment advances
Lang, E., & van Rhee, F. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101161 · Cited by 29
Saeed-Abdul-Rahman, I., & Al-Amri, A. (2012) · The Korean Journal of Hematology · doi:10.5045/kjh.2012.47.3.163 · Cited by 27
“[36] noted an elevated concentration of IL-6 in a patient with UCD, which normalized after lymph node excision along with the disappearance of clinical and biologic abnormalities.”
BackgroundHiguchi, T., Nakanishi, T., Takada, K., Matsumoto, M., Okada, M., Horikoshi, H., & Suzuki, K. (2010) · Journal of Korean medical science · doi:10.3346/jkms.2010.25.9.1364 · Cited by 27
“IL-6 production by the germinal center B cells in the swollen lymph nodes of patients with MCD is remarkable (8), but the roles of T cells are unknown.”
BackgroundBlockade of viral interleukin-6 expression of Kaposi's sarcoma–associated herpesvirus
Zhang, Y.-J., Bonaparte, R. S., Patel, D., Stein, D. A., & Iversen, P. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2036 · Cited by 27
Massive pleural effusion: an unusual presentation of Castleman's disease.
Reynolds, S., Gibbs, A., Weeks, R., Adams, H., & Davies, B. (1992) · European Respiratory Journal · doi:10.1183/09031936.93.05091150 · Cited by 27
Lymphokine Production by B Cells from Normal and HIV‐Infected Individuals
Kehrl, J., Rieckmann, P., Kozlow, E., & Fauci, A. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb24617.x · Cited by 27
Nishikori, A., Nishimura, M. F., Nishimura, Y., Notohara, K., Satou, A., Moriyama, M., Nakamura, S., & Sato, Y. (2021) · Pathology international (Print) · doi:10.1111/pin.13185 · Cited by 26
“Overproduction of IL‐6 is deeply related to PC‐ iMCD pathogenesis.(20) IL‐6 is produced by a variety of cells, including T cells, B cells, and macrophages.”
BackgroundInfluentialThe management of Castleman disease
Lomas, O., Streetly, M., Pratt, G., Cavet, J., Royston, D., Schey, S., & Ramasamy, K. (2021) · British Journal of Haematology · doi:10.1111/bjh.17688 · Cited by 26
“Thalidomide has been shown to exert its anti-inflammatory effects partly via suppression of IL-6 signalling.62 The long-term continuation of thalidomide has been reported to be associated with prolonged disease control in MCD.63,64 Rituximab (4 weeks) and thalidomide (1–3 months) in combination have been observed in a…”
BackgroundInfluential
Metadata
- Authors
- Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T.
- Affiliations
- The University of Osaka (JP)
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1989-09-01
- Volume
- 74
- Issue
- 4
- Pages
- 1360-1367
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1632068222
- Cited by
- 928
- References
- 0
- Citations by year
- 2026: 11 · 2025: 27 · 2024: 23 · 2023: 15 · 2022: 29 · 2021: 20 · 2020: 32 · 2019: 18 · 2018: 33 · 2017: 37 · 2016: 21 · 2015: 38 · 2014: 35 · 2013: 34 · 2012: 25
- FWCI
- 14.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Blood (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphadenopathy Diagnosis and Analysis
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Keywords
- Castleman disease, interleukin-6, germinal center, B cells, lymph node hyperplasia, hypergammaglobulinemia, acute phase proteins, plasma cell infiltration, surgical resection, cytokine production
- MeSH terms
- Adolescent, Female, Castleman Disease, Humans, Interleukins, Lymph Node Excision, Lymph Nodes, Lymphatic Diseases, Middle Aged, Interleukin-6
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
